Prescribing Brexpiprazole

Why Brexpiprazole Matters, and Where It Doesn't

Brexpiprazole (Rexulti) is aripiprazole's younger, quieter sibling. Both are dopamine D2 partial agonists, the third-generation mechanism that lets them stabilize dopamine tone rather than simply block it. The pitch when Otsuka and Lundbeck launched brexpiprazole in 2015 was that it delivers aripiprazole's low metabolic and prolactin burden with less akathisia and less activation: a smoother partial agonist for patients who found aripiprazole too jittery.

That is roughly true, and it is roughly the whole story. Brexpiprazole is a genuinely useful, generally well-tolerated agent with a narrow, specific set of jobs:

1. Adjunctive treatment of major depressive disorder, its highest-volume, most defensible use.
2. Schizophrenia (ages 13+), effective but unremarkable within the class.
3. Agitation associated with Alzheimer's dementia, the first and only FDA-approved drug for this indication (2023), but with modest benefit and a mortality signal that demands caution.

What brexpiprazole is not: it is not a mood stabilizer (two RCTs showed it is no better than placebo in acute mania, do not use it there), it is not FDA-approved for PTSD (the application was rejected), and it is not cheap. As of this writing it remains brand-only (alongside Caplyta, Fanapt, and Vraylar) while aripiprazole, its near-twin, is available generically for a fraction of the cost.

The governing thesis of this guide: brexpiprazole is a clean, low-dose partial agonist whose real value is as an adjunct in MDD. Reach for it when a patient needs aripiprazole's mechanism but couldn't tolerate aripiprazole's activation, and be honest that in most other situations, a generic does the same job for less money.

Part 1: Indications: Who Is Brexpiprazole For?

FDA-Approved Uses

• Adjunctive treatment of major depressive disorder in adults (add-on to an antidepressant)
• Schizophrenia in adults and adolescents (ages 13 and up)
• Agitation associated with dementia of the Alzheimer's type (approved May 2023)

Adjunctive MDD: the sweet spot

This is where brexpiprazole earns its keep. Roughly a third to a half of depressed patients don't remit on an adequate antidepressant trial, and augmentation with a dopamine partial agonist is a mainstream next step. Brexpiprazole is added to an ongoing SSRI/SNRI when the patient has had a partial or non-response.

The evidence base is solid but not spectacular. In pooled MDD augmentation data, the effect size is small (standardized mean difference ~0.31). In network meta-analyses of dopaminergic augmenters, the efficacy hierarchy is consistent:

So brexpiprazole augmentation is real but modest, better than cariprazine, slightly behind aripiprazole. The reason to pick it over generic aripiprazole is almost never superior efficacy; it is tolerability, specifically, less akathisia and less activation in a patient who is already anxious or agitated, or who has failed aripiprazole for those reasons.

Schizophrenia: effective but unremarkable

Brexpiprazole works for schizophrenia, both acute and maintenance, with the low EPS and low metabolic/prolactin liability characteristic of the partial-agonist class. But the CATIE-era lesson holds: all atypicals are roughly equally effective for psychosis; you choose by side-effect profile and cost. Within that logic, brexpiprazole's smoother tolerability is a point in its favor, and its price is a point against it. It is a reasonable choice for a patient who needs a partial agonist but found aripiprazole too activating; otherwise generic aripiprazole is the default.

Agitation in Alzheimer's dementia: a first, but a cautious one

Brexpiprazole holds the distinction of being the only FDA-approved agent for agitation in Alzheimer's dementia (approved 2023 on the strength of three 12-week RCTs, ~1,048 patients). That is a genuine milestone in a space where clinicians have long reached off-label for quetiapine, risperidone, aripiprazole, and olanzapine. But temper expectations:

• The benefit is statistically significant but clinically modest: roughly a 5-point reduction on the Cohen-Mansfield Agitation Inventory (a 174-point scale), against a validated "clinically meaningful" threshold of about 17 points.
• Efficacy was seen only at 2–3 mg/day; the lower 0.5–1 mg doses did not separate from placebo.
• Post-hoc analysis showed the benefit was not driven by improvement in psychosis/paranoia; it acted on agitation per se.
• A mortality signal was present: in the dementia trials, deaths ran higher on drug than placebo (roughly 0.9% vs 0.3%). Investigators judged the deaths treatment-unrelated, but the signal is real and sits atop the class boxed warning.

What NOT to use it for

• Acute bipolar mania: Two RCTs (654 patients, 3 weeks, titrated 2→4 mg) showed brexpiprazole no better than placebo on YMRS. Use an FDA-approved antimanic (aripiprazole, asenapine, cariprazine, olanzapine, quetiapine, risperidone, ziprasidone) instead.
• PTSD: Studied as an adjunct to sertraline with a positive single RCT (CAPS-5 −19.2 vs −13.6 for sertraline alone), but the FDA rejected the indication: only one of two pivotal trials was positive, the effect was significant mainly in women, and dropout/design problems muddied the data. Not an evidence-based choice.

Part 2: Before You Start: Workup and Candidacy

Brexpiprazole requires far less pre-start machinery than lithium or clozapine. But it is still an atypical antipsychotic, and the metabolic monitoring framework applies.

Baseline workup

Who is a poor candidate?

• Dementia with Lewy bodies: antipsychotics are relatively contraindicated (high risk of neuroleptic malignant syndrome, severe sensitivity reactions, delirium, and death). Avoid brexpiprazole here.
• Elderly patients with dementia-related psychosis treated off-label for psychosis rather than the approved agitation indication: the boxed-warning mortality risk applies.
• Known hypersensitivity to brexpiprazole.
• Bear in mind CYP2D6 poor metabolizers and patients on strong CYP-interacting drugs need dose adjustment (see Part 7), not a contraindication, but a dosing modification.

Part 3: How to Start and Dose

Formulation

Brexpiprazole comes as oral tablets in 0.25, 0.5, 1, 2, 3, and 4 mg strengths. Once-daily dosing, with or without food. There is no long-acting injectable and no liquid. The granular low-dose tablets (0.25, 0.5 mg) exist specifically to support the slow titration this drug rewards.

Dosing by indication

Adjunctive MDD (adults):

• Start: 0.5 mg or 1 mg once daily added to the existing antidepressant.
• Titrate: to 1 mg, then to the target of 2 mg once daily, at intervals of at least a week.
• Maximum: 3 mg/day, but note that efficacy plateaus at 2 mg and dropouts for adverse effects climb above it. The modeled optimal dose is ~1.6–1.8 mg (ED50 ≈ 0.88 mg, ED95 ≈ 1.79 mg). In practice, 1–2 mg is the therapeutic window; 2 mg is the usual destination.

Schizophrenia (adults):

• Start: 1 mg once daily.
• Titrate: to 2 mg on day 5–7, then to 4 mg by day 8 as tolerated.
• Target: 2–4 mg/day; maximum 4 mg/day.

Schizophrenia (adolescents 13–17): same 4 mg/day target, reached by gradual titration from 0.5–1 mg.

Agitation in Alzheimer's dementia:

• Start: 0.5 mg once daily (bedtime is reasonable given mild sedation).
• Titrate: +0.5 mg weekly.
• Target: 2–3 mg/day (the doses that showed efficacy); maximum 3 mg/day.
• Duration studied: 12 weeks. Plan a taper attempt after ~3 months of stability (see Discontinuation).

The half-life makes this a "slow" drug

Brexpiprazole has a long elimination half-life (~91 hours for the parent; its major metabolite (DM-3411) has a similar half-life of about 86 hours but is not considered to contribute clinically), so:

• Steady state takes 10–14 days after any dose change.
• Once-daily dosing is more than adequate; there is never a reason to split it.
• Do not judge efficacy or push the dose for at least a week or two after a change: you haven't seen the full effect yet.
• The flip side: a missed dose is forgiving (levels fall slowly), and on discontinuation the drug self-tapers to some degree over days, but do not rely on this in place of a deliberate taper.

Part 4: Monitoring: The Schedule

Brexpiprazole follows the standard metabolically "cleaner" atypical monitoring cadence, lighter than olanzapine/clozapine, but not zero.

Act on:

• ≥5–7% weight gain from baseline: intervene early (lifestyle, consider metformin, consider switching).
• Fasting glucose 100–125: prediabetes range, monitor closely; ≥126: diabetes workup.
• Triglycerides rising >150: often the first metabolic signal.
• New restlessness/inner tension: screen for akathisia (below), don't dismiss as anxiety.
• Any abnormal involuntary movements: formal AIMS, reassess the drug.

Elderly dementia patients warrant closer clinical follow-up given the mortality signal; reassess ongoing need at every visit.

Part 5: Side Effects and How to Manage Them

Brexpiprazole is, by antipsychotic standards, well tolerated. Its signature advantage over aripiprazole is less akathisia and less activation. But it is still an atypical, and the class liabilities (weight, movement, sedation) all apply in muted form.

Akathisia and EPS

Akathisia (inner restlessness, inability to sit still) is the most clinically important movement side effect of the partial agonists, and it was the most common adverse event in the mania trials. Brexpiprazole's real selling point is that it causes less akathisia than aripiprazole at comparable clinical exposure, but "less" is not "none."

Management, stepped:

1. Lower the dose (akathisia is dose-related) or slow the titration.
2. Propranolol 20 mg BID–TID, titrated up to ~240 mg/day as pulse allows (hold if pulse <60). Beta-blockade is first-line and often more effective than anticholinergics for akathisia.
3. Benzodiazepine for rapid bridging relief: clonazepam 0.5 mg BID standing ± PRN, while propranolol is titrated.
4. Mirtazapine ≤15 mg QHS has RCT support as a longer-term option (caution: >15 mg can cause akathisia).
5. Do not reach for anticholinergics (benztropine) for akathisia; they treat parkinsonism/dystonia, not akathisia.

Frank parkinsonism and dystonia are uncommon at these low doses; if they occur, an anticholinergic (benztropine 0.5–2 mg) or dose reduction is appropriate.

Weight gain and metabolic effects

Brexpiprazole sits toward the favorable end of the metabolic spectrum, closer to aripiprazole than to olanzapine or quetiapine, but it is not metabolically neutral. Modest weight gain and lipid/glucose shifts occur, and triglycerides often move first.

Management:

• Lifestyle first: portion control (a simple, concrete instruction: reduce the plate by ~25%), activity, dietary counseling.
• Metformin is the evidence-based pharmacologic add-on: start 500 mg BID, titrate to 1,000 mg BID; meta-analytic data show ~3–4 kg (up to ~7 lb) attenuation of antipsychotic weight gain, plus benefits to insulin sensitivity, A1c, and lipids. Monitor for GI upset and the rare lactic acidosis; check an annual metabolic panel.
• Switch to an even leaner agent (or back to generic aripiprazole/ziprasidone/lurasidone) if gain is significant and early.

Sedation / somnolence and activation

Compared with aripiprazole, brexpiprazole is slightly more sedating and less activating, often an advantage in an anxious, agitated, or insomniac patient, occasionally a nuisance.

• If sedating: dose in the evening.
• If activating/insomnia (less common than with aripiprazole): dose in the morning; reassure it often settles.

Nausea and fatigue

Common early, usually transient. Take with food; reassure; typically resolves over the first week or two.

Tardive dyskinesia (the long-term class risk)

Like all antipsychotics, brexpiprazole carries a cumulative TD risk (atypicals ~1%/year, lower than typicals). Partial agonists are relatively lower-risk, but not exempt.

• Screen with a periodic AIMS.
• If TD emerges: reassess the need for the antipsychotic; a VMAT2 inhibitor (valbenazine, deutetrabenazine) is the evidence-based treatment. Anticholinergics do not treat TD (and can worsen it).

Impulse-control / compulsive behaviors

A recognized class effect of dopamine partial agonists (well documented with aripiprazole): pathological gambling, hypersexuality, compulsive shopping/eating. Ask about it at baseline and follow-up; it resolves on dose reduction or discontinuation. Warn patients and families explicitly.

Cardiac / QT

Brexpiprazole shows no meaningful QT prolongation (confirmed in dementia trials), and no increase in falls, fractures, or cerebrovascular events was seen in those trials. Routine ECG is not required absent cardiac risk factors or QT-prolonging co-medications.

Part 6: Overdose, Toxicity, and Boxed Warnings

Boxed warnings (class-wide)

Brexpiprazole carries two FDA boxed warnings, both inherited from the classes it straddles: antipsychotics, and antidepressant-adjunct therapy.

Neuroleptic malignant syndrome (NMS)

Rare but life-threatening class risk: hyperthermia, rigidity, altered mental status, autonomic instability. Especially elevated in dementia with Lewy bodies, a reason to avoid brexpiprazole there. Management: stop the drug, supportive/ICU care, cooling; dantrolene or bromocriptine if severe.

Overdose

There is no specific antidote. Brexpiprazole overdose is managed supportively: airway, cardiac monitoring, treat hypotension and arrhythmia symptomatically. Its long half-life means effects can be prolonged; observe accordingly. As a partial agonist it is generally less dangerous in overdose than many full antagonists, but treat every ingestion as a medical evaluation.

Part 7: Drug Interactions

Brexpiprazole is metabolized by CYP3A4 and CYP2D6. Because both pathways matter, interactions and pharmacogenetics both bear on dosing. The general rule: strong inhibitors → halve or quarter the dose; strong inducers → the drug won't work; poor 2D6 metabolizers → halve the dose.

Dose adjustments (the ones worth memorizing)

Pharmacodynamic interactions

• CNS depressants (alcohol, benzodiazepines, opioids, sedating antihistamines): additive sedation.
• Antihypertensives: additive hypotension (modest; brexpiprazole causes little orthostasis on its own).
• QT-prolonging drugs: brexpiprazole itself is QT-neutral, but be thoughtful about additive risk from other agents.

Sertraline (a weak 2D6 inhibitor) was used at 150 mg alongside brexpiprazole in the PTSD trials without a clinically significant interaction, a reasonable augmentation partner from an interaction standpoint.

Part 8: Special Populations

Pregnancy

Human data are limited (brexpiprazole is a newer agent). Two general principles govern:

• Antipsychotics as a class carry a third-trimester risk of neonatal extrapyramidal and withdrawal symptoms (agitation, hypertonia/hypotonia, tremor, feeding difficulty, respiratory distress); monitor the neonate.
• Untreated maternal illness carries real risk too. For a patient who needs an antipsychotic, the decision is individualized with OB and the patient. Where feasible, agents with more reproductive-safety data (e.g., older agents, or aripiprazole for the same mechanism) may be preferred simply because we know more about them.
• A pregnancy exposure registry exists for atypical antipsychotics; enroll patients who continue treatment.

Lactation

Data are sparse. Small amounts likely enter breast milk (as with other atypicals). If a patient breastfeeds while taking it, monitor the infant for sedation, poor feeding, and irritability, in coordination with pediatrics. Many clinicians prefer agents with more lactation data if a choice exists.

Elderly

• Start low, go slow: the 0.5 mg increments exist for this.
• The dementia mortality boxed warning dominates the risk calculus. For the approved agitation indication, dose to 2–3 mg but reassess need continually and plan to taper.
• Watch for orthostasis (modest with this drug), sedation, and anticholinergic-type confusion (also modest).

Hepatic and renal impairment

• Moderate-to-severe hepatic impairment (Child-Pugh ≥7) or moderate-to-severe renal impairment (CrCl <60): the label caps the maximum dose (generally 2 mg/day in MDD and 3 mg/day in schizophrenia) because clearance is reduced. Titrate cautiously to these lower ceilings.
• Mild impairment does not require adjustment.

Pediatric / adolescent

• Schizophrenia is approved from age 13, targeting 4 mg/day via gradual titration.
• No approval in younger children or for pediatric MDD/agitation. Monitor metabolic parameters closely; youth are more vulnerable to antipsychotic weight gain, and remember the antidepressant suicidality warning if used adjunctively.

Part 9: Discontinuation

Brexpiprazole lacks a defined physiologic withdrawal syndrome, but two class phenomena apply, and its long half-life is a built-in cushion.

• Dopamine supersensitivity / rebound. Chronic D2 modulation upregulates receptors; abrupt withdrawal can produce rebound psychosis or withdrawal-emergent dyskinesia (choreiform movements, dystonia, peaking 1–4 weeks after stopping). Taper rather than stop cold, especially in schizophrenia.
• Relapse. As with any maintenance agent, discontinuation raises relapse risk; the decision to stop is a clinical one weighing stability, episode history, and patient preference.

How to taper:

• The long half-life (~91 h parent, ~86 h metabolite) means the drug self-tapers over roughly a week or two once stopped, gentler than short-half-life agents. Even so, in stable maintenance patients a deliberate reduction (e.g., halve, then halve again, over weeks) is prudent, watching the low end of the taper where breakthrough is most likely.
• In dementia agitation: after ~3 months of stability, attempt a taper (reduce ~25% every 1–2 weeks). Many agitation episodes are driven by a resolvable trigger, and continued antipsychotic exposure in dementia carries the mortality liability, so deprescribing is the goal, not indefinite treatment.

Part 10: Brexpiprazole vs the Alternatives

vs Aripiprazole: the essential comparison

This is the decision that defines brexpiprazole's role. Same mechanism (D2/5-HT1A partial agonist), same favorable metabolic and prolactin profile. Differences:

• Aripiprazole: slightly higher antidepressant augmentation effect size (SMD 0.38 vs 0.31), generic (large cost advantage), but more akathisia and more activation/insomnia.
• Brexpiprazole: less akathisia, less activation, mildly more sedation; brand-only (expensive).

The clean decision rule: default to generic aripiprazole; switch to brexpiprazole for the patient who benefited from aripiprazole's mechanism but couldn't tolerate its akathisia or activation, or an anxious/agitated patient in whom you want to avoid activation from the start (and whose insurance will cover it).

vs Cariprazine

Cariprazine is the third partial-agonist option. For MDD augmentation it is the weakest of the three (SMD ~0.13). Brexpiprazole beats it there. Cariprazine's distinct niche is bipolar depression and mania (where brexpiprazole fails), and its very long-half-life metabolite gives it a different profile.

vs Quetiapine, olanzapine, risperidone (as MDD augmenters / antipsychotics)

• Quetiapine and olanzapine have MDD-augmentation data but carry much heavier metabolic and sedation burdens. Brexpiprazole wins on tolerability.
• Risperidone augmentation shows modest benefit (e.g., MADRS remission ~52% vs 24% placebo in one trial) but adds prolactin elevation and weight; brexpiprazole avoids both.
• For dementia agitation, the off-label alternatives (risperidone 0.5–2 mg, aripiprazole 2–5 mg, quetiapine 50–100 mg, olanzapine 2.5–5 mg) are cheaper and well-established; brexpiprazole's only edge is the FDA label.

The honest bottom line

Brexpiprazole is a well-tolerated, low-EPS, metabolically-favorable partial agonist whose efficacy is solid-but-modest and whose chief liability is cost relative to generic aripiprazole. It is the right answer for a specific patient, the one who needs this mechanism but not aripiprazole's rough edges, and the wrong answer as a reflexive first choice when a generic would do.

Mechanism: The Short Version

Brexpiprazole is a serotonin-dopamine activity modulator, the third-generation partial-agonist class alongside aripiprazole, cariprazine, and lumateperone. Its core actions:

• Partial agonist at dopamine D2 (and D3): it occupies the receptor and provides a fraction of full dopamine signaling. Where dopamine is high (mesolimbic hyperdopaminergia of psychosis) it acts as a functional antagonist, dampening signaling; where dopamine is low it provides tone. This "dopamine thermostat" is why partial agonists cause less EPS, less prolactin elevation, and fewer metabolic effects than full D2 blockers.
• Partial agonist at serotonin 5-HT1A: contributes to anxiolytic/antidepressant effects and further reduces EPS.
• Antagonist at 5-HT2A: the classic atypical action that spares nigrostriatal dopamine.

The clinically relevant difference from aripiprazole is lower intrinsic activity at D2 (a "weaker" partial agonist) plus stronger 5-HT1A/5-HT2A engagement, the pharmacologic basis for less akathisia and less activation. In animal fear-conditioning models it has shown effects on memory consolidation (the rationale behind the PTSD investigation), though that never translated into an approved human indication.

Bedside Cheat Sheet